19S regulatory particle of the proteasome (19S RP)

The **19S regulatory particle** is a large multisubunit complex that forms the regulatory "cap" of the 26S proteasome, a central proteolytic machine in eukaryotic cells. Its main function is to recognize, bind, deubiquitinate, and unfold polyubiquitinated proteins, then translocate them into the 20S core particle for proteolytic degradation[1][5][7][3]. The 19S regulatory particle is composed of approximately 19 subunits and can be subdivided into two subcomplexes: the **base**, which contains six AAA-family ATPases (Rpt1-6) and non-ATPase scaffolding and substrate receptor proteins (e.g., Rpn1, Rpn2, Rpn10, Rpn13), and the **lid**, composed of non-ATPase subunits (e.g., Rpn3, Rpn5-9, Rpn11, Rpn12)[2][4][8][7]. The 19S regulatory particle is crucial for the specificity and processivity of the ubiquitin–proteasome system, ensuring that only properly tagged proteins are degraded. Dysregulation or mutations in 19S subunits have been implicated in cancer and neurodegenerative diseases due to impaired protein homeostasis. While current clinically approved proteasome inhibitors (e.g., bortezomib) mainly target the 20S proteolytic core, the 19S particle is an emerging drug target, particularly its deubiquitinase and ATPase components[8][5][7]. In summary, the **19S regulatory particle** is an essential, non-catalytic subcomplex of the 26S proteasome, making it a valid and emerging **therapeutic target** for diseases characterized by disrupted protein degradation pathways.

Other names

19S regulatory particlePA70019S proteasome complex19S complex19S regulator19S cap19S regulatory cap

Inhibitors block proteasomal protein degradation by targeting catalytic or regulatory subunits, resulting in accumulation of polyubiquitinated proteins, cell cycle arrest, and apoptotic cell death[8][5]. Some drugs or tool compounds inhibit functions unique to the 19S, such as deubiquitinating enzymes or ATPase activity, interfering with substrate recognition/unfolding[7].